Abcellera Biologics Inc.2025财年第一财季实现净利润-45.62百万美元，同比减少12.34%

市场透视2025-05-18

5月18日，Abcellera Biologics Inc.（ABCL.US）公布财报，公告显示公司2025财年第一财季净利润为-45.62百万美元，同比减少12.34%；其中营业收入为4.24百万美元，同比减少57.39%，每股基本收益为-0.15美元。从资产负债表来看，Abcellera Biologics Inc.（ABCL.US）总负债1.64亿美元，其中短期债务4.64百万美元，资产负债...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2536582570?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-18 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2536582570","market":"us","top_or_hot":-1,"title":"Abcellera Biologics Inc.2025财年第一财季实现净利润-45.62百万美元，同比减少12.34%","media":"市场透视","content":"<div>\n<p>5月18日，Abcellera Biologics Inc.（ABCL.US）公布财报，公告显示公司2025财年第一财季净利润为-45.62百万美元，同比减少12.34%；其中营业收入为4.24百万美元，同比减少57.39%，每股基本收益为-0.15美元。从资产负债表来看，Abcellera Biologics Inc.（ABCL.US）总负债1.64亿美元，其中短期债务4.64百万美元，资产负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000335a6e2d8bf&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abcellera Biologics Inc.2025财年第一财季实现净利润-45.62百万美元，同比减少12.34%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbcellera Biologics Inc.2025财年第一财季实现净利润-45.62百万美元，同比减少12.34%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-18 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000335a6e2d8bf&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月18日，Abcellera Biologics Inc.（ABCL.US）公布财报，公告显示公司2025财年第一财季净利润为-45.62百万美元，同比减少12.34%；其中营业收入为4.24百万美元，同比减少57.39%，每股基本收益为-0.15美元。从资产负债表来看，Abcellera Biologics Inc.（ABCL.US）总负债1.64亿美元，其中短期债务4.64百万美元，资产负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000335a6e2d8bf&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABCL","symbol_name":"AbCellera Biologics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000335a6e2d8bf&s=b","article_id":"2536582570","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000335a6e2d8bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2536582570","pubTimestamp":1747497642,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月18日，Abcellera Biologics Inc.公布财报，公告显示公司2025财年第一财季净利润为-45.62百万美元，同比减少12.34%；其中营业收入为4.24百万美元，同比减少57.39%，每股基本收益为-0.15美元。从资产负债表来看，Abcellera Biologics Inc.总负债1.64亿美元，其中短期债务4.64百万美元，资产负债比为8.20，流动比率为0.11。机构评级：截至2025年5月18日，当前有7家机构对Abcellera Biologics Inc.目标价做出预测，其中目标均价为8.43美元，其中最低目标价为5.00美元，最高目标价为17.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ABCL":"AbCellera Biologics"},"translate_title":"Abcellera Biologics Inc. achieved net profit of-45.62 million in the first fiscal quarter of fiscal year 2025, a year-on-year decrease of 12.34%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":0.9},"content_text":"5月18日，Abcellera Biologics Inc.（ABCL.US）公布财报，公告显示公司2025财年第一财季净利润为-45.62百万美元，同比减少12.34%；其中营业收入为4.24百万美元，同比减少57.39%，每股基本收益为-0.15美元。从资产负债表来看，Abcellera Biologics Inc.（ABCL.US）总负债1.64亿美元，其中短期债务4.64百万美元，资产负债比为8.20，流动比率为0.11。机构评级：截至2025年5月18日，当前有7家机构对Abcellera Biologics Inc.目标价做出预测，其中目标均价为8.43美元，其中最低目标价为5.00美元，最高目标价为17.00美元。公司简介：AbCellera Biologics Inc 是一家专门设计用于克服传统发现障碍的抗体发现和开发引擎，能够以更高的精确度和速度找到最佳临床候选药物，更快地用于临床和患者。凭借集成的AbCellera平台，公司的专家能够快速搜索广泛的多样化抗体，挑选出有效且可开发的先导药物，为合作伙伴的持久成功奠定基础。该公司在与新兴生物技术和制药公司建立合作伙伴关系方面拥有丰富经验。AbCellera利用其专有的硬件、软件和工具，结合最新的数据科学，作为战略合作伙伴，帮助任何项目更快地开发出优化的解决方案。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2536582570","isCrawlerRequest":true}